Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.5M
1M shares
52-week range
$5.04 – $12.05
13% from low
Exchange
NASDAQ
ADRC
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
www.addextherapeutics.comNo one on the platform currently holds ADXN.
No tracked institution reports a position in ADXN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-10-23 | 1-for-20reverse |
No one on the platform has traded ADXN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ADXN Its lead programs focus on neurological disorders, including GPR52 modulation for Parkinson’s disease, targeting a large unmet medical need...
View on StockTwits ↗$ADXN Neurosterix Phase 1 study NTX-253 in Schizophrenia data should be in the coming weeks. decent R/R.
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-6-25-addex-therapeutics-ltd-stock/ $ADXN Addex Therapeutics Earnings Transcript
View on StockTwits ↗$ADXN So after these great results , can we expect the pumpers to return, did not think so.
View on StockTwits ↗$ADXN https://www.addextherapeutics.com/en/investors/press-releases/addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update/
View on StockTwits ↗$ADXN $DFTX / $MLTX / $CVM — From the Biotech World Today: Four Smaller Headlines Worth Watching https://www.merlintrader.com/biotech-world-smaller-headlines-jun22/
View on StockTwits ↗$ADXN will report its Q1 2026 results on June 25 and host a conference call.
View on StockTwits ↗$ADXN Brilliant piece that captures ADXN's situation perfectly. So if you want to update your understanding of ADXN or get to know ADXN better, this is essential reading. https://everyticker.com/quote/ADXN/analysis/addex-therapeutics-a-9-million-option-ticket-on-neurosterix-s-success-nasdaq-adxn
View on StockTwits ↗$RXRX $CAI $VRDN $ADXN $ANVS (Sorry, using this is a placeholder to see how these track over time. Posting late so as to not clog the boards or appear as spam.)
View on StockTwits ↗$ADXN Q2 '25 Earnings Results & Recap Addex Therapeutics reported a net loss of CHF6.7M for 2025, compared to a net profit of CHF7.1M in 2024, with basic and diluted loss per share at CHF 0.06. Cash position was CHF1.6M.
View on StockTwits ↗$ADXN https://www.addextherapeutics.com/en/investors/press-releases/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-non-human-primate-chronic-cough-model/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1M | +0.0% | $-4.74 | $-4.74–$-4.74 | — | 2 |
| 2027 | $6M | +332.5% | $-3.24 | $-3.24–$-3.24 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-30 | $-1.42 | $-1.94 | -36.0% |
| 2025-11-10 | $-1.42 | $-2.91 | -104.4% |
| 2025-06-20 | $-4.26 | $-1.33 | +68.8% |
| 2025-04-07 | $-1.42 | $-1.63 | -14.7% |
| 2024-11-22 | $-1.40 | $-2.77 | -97.9% |
| 2024-09-30 | $-0.01 | $-1.77 | -17600.0% |
| $47M |
| — |
| MTNBMatinas BioPharma Holdings, Inc. | $0.23 | -2.92% | $1M | — |
| NBYNovaBay Pharmaceuticals, Inc. | $1.47 | -24.62% | $39M | — |
Source: Financial Modeling Prep · peers by sector/industry